Gui Zhi Fu Ling Wan significantly reduced menstrual pain in primary dysmenorrhea patients with heat-burning blood-stasis syndrome, without notable adverse effects.
In the methodology, a randomized, double-blinded, placebo-controlled trial was conducted. Eligible patients suffering from primary dysmenorrhea with heat-burning blood-stasis syndrome were randomly placed into two groups – one received Guizhi Fuling Wan, the other a placebo, administered twice daily across three menstrual cycles, with a 3-month follow-up. The primary measurement was the change in pain intensity from the beginning to the 6th month, gauged by using a Visual Analog Scale.
In the discussion of results, data showed that the pain intensity (measured using Visual Analog Scale) significantly decreased in the Guizhi Fuling Wan group compared to the placebo over the 6 month period. Secondary measurements also indicated a greater reduction in Cox Menstrual Symptom Scale, Self-rating Anxiety Scale, and traditional Chinese medicine syndrome scores in the Guizhi Fuling Wan group compared to the placebo. However, there was no significant difference between the two groups when measuring the Self-rating Depression Scale. Furthermore, no serious adverse events were observed during the trial.
